Literature DB >> 16522281

Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes.

Susanne Trost1, Richard Pratley, Burton Sobel.   

Abstract

Patients with the metabolic syndrome are insulin resistant and manifest a cluster of risk factors for cardiovascular disease. Impaired fibrinolysis and increased concentrations in blood of plasminogen activator inhibitor-1 (PAI-1) are related to insulin resistance and abdominal obesity and may contribute to the increased risk for cardiovascular disease in this group. Weight loss, metformin, and thiazolidinediones ameliorate insulin resistance and decrease concentrations of PAI-1. Thus, they may lower risk in patients with the metabolic syndrome.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16522281     DOI： 10.1007/s11892-006-0052-5

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


  89 in total

1.  Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture.

Authors:  T Skurk; Y M Lee; H Hauner
Journal:  Hypertension       Date:  2001-05       Impact factor: 10.190

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice.

Authors:  S Konstantinides; K Schäfer; T Thinnes; D J Loskutoff
Journal:  Circulation       Date:  2001-01-30       Impact factor: 29.690

4.  Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Authors:  B Isomaa; P Almgren; T Tuomi; B Forsén; K Lahti; M Nissén; M R Taskinen; L Groop
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

5.  Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity.

Authors:  I Shimomura; T Funahashi; M Takahashi; K Maeda; K Kotani; T Nakamura; S Yamashita; M Miura; Y Fukuda; K Takemura; K Tokunaga; Y Matsuzawa
Journal:  Nat Med       Date:  1996-07       Impact factor: 53.440

6.  Microarray profiling of isolated abdominal subcutaneous adipocytes from obese vs non-obese Pima Indians: increased expression of inflammation-related genes.

Authors:  Y H Lee; S Nair; E Rousseau; D B Allison; G P Page; P A Tataranni; C Bogardus; P A Permana
Journal:  Diabetologia       Date:  2005-07-30       Impact factor: 10.122

Review 7.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Richard Kahn; John Buse; Ele Ferrannini; Michael Stern
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

8.  High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

Authors:  A M Thögersen; J H Jansson; K Boman; T K Nilsson; L Weinehall; F Huhtasaari; G Hallmans
Journal:  Circulation       Date:  1998-11-24       Impact factor: 29.690

9.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

10.  Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

Authors:  A Hamsten; U de Faire; G Walldius; G Dahlén; A Szamosi; C Landou; M Blombäck; B Wiman
Journal:  Lancet       Date:  1987-07-04       Impact factor: 79.321
View more
  16 in total

Review 1.  Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases.

Authors:  Anna Tjärnlund-Wolf; Helen Brogren; Eng H Lo; Xiaoying Wang
Journal:  Stroke       Date:  2012-08-09       Impact factor: 7.914

2.  The association of inflammatory and fibrinolytic proteins with 5 year change in insulin clearance: the Insulin Resistance Atherosclerosis Study (IRAS).

Authors:  C C Lee; C Lorenzo; S M Haffner; L E Wagenknecht; A Festa; M O Goodarzi; D Stefanovski; N C Olson; J M Norris; M J Rewers; A J Hanley
Journal:  Diabetologia       Date:  2012-10-10       Impact factor: 10.122

3.  Impaired leptomeningeal collateral flow contributes to the poor outcome following experimental stroke in the Type 2 diabetic mice.

Authors:  Yosuke Akamatsu; Yasuo Nishijima; Chih Cheng Lee; Shih Yen Yang; Lei Shi; Lin An; Ruikang K Wang; Teiji Tominaga; Jialing Liu
Journal:  J Neurosci       Date:  2015-03-04       Impact factor: 6.167

4.  Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis.

Authors:  Jose A Diaz; Nicole E Ballard-Lipka; Diana M Farris; Angela E Hawley; Shirley K Wrobleski; Daniel D Myers; Peter K Henke; Daniel A Lawrence; Thomas W Wakefield
Journal:  J Vasc Surg       Date:  2011-11-25       Impact factor: 4.268

5.  Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Authors:  Burton E Sobel; Regina M Hardison; Saul Genuth; Maria M Brooks; Robert D McBane; David J Schneider; Richard E Pratley; Kurt Huber; Robert Wolk; Ashok Krishnaswami; Robert L Frye
Journal:  Circulation       Date:  2011-07-18       Impact factor: 29.690

6.  Non-Alcoholic Fatty Liver Disease (NAFLD) - Is it an Emerging Risk Factor for Coronary Artery Disease?: Preliminary study in a local Indian population.

Authors:  Manopriya Thiruvagounder; Shaheen Khan; Dhastagir S Sheriff
Journal:  Sultan Qaboos Univ Med J       Date:  2010-07-19

7.  Age-related short-term effect of ramipril on N-terminal pro-brain natriuretic peptide and markers of hemostasis in patients after acute myocardial infarction.

Authors:  Andreja Sinkovic
Journal:  Wien Klin Wochenschr       Date:  2010-05       Impact factor: 1.704

8.  Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease.

Authors:  Victor L Serebruany; Alex Malinin; Stephen Ong; Dan Atar
Journal:  J Thromb Thrombolysis       Date:  2007-05-26       Impact factor: 2.300

9.  Vascular Risk Factors in Patients with Different Subtypes of Ischemic Stroke May Affect Their Outcome after Intravenous tPA.

Authors:  Yi Dong; Wenjie Cao; Jinma Ren; Deepak S Nair; Sarah Parker; Jan L Jahnel; Teresa G Swanson-Devlin; Judith M Beck; Maureen Mathews; Clayton J McNeil; Manas Upadhyaya; Yuan Gao; Qiang Dong; David Z Wang
Journal:  PLoS One       Date:  2015-08-06       Impact factor: 3.240

10.  Association of PAI-1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT).

Authors:  Nasrin Azad; Lily Agrawal; Nicholas V Emanuele; Ronald Klein; Gideon D Bahn; Madeline McCarren; Peter Reaven; Rodney Hayward; William Duckworth
Journal:  Diabetes Care       Date:  2013-10-07       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.